ANDA 210967, held by Eugia Pharma. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 210967 (Dexamethasone Sodium Phosphate), held by Eugia Pharma, was first approved by FDA on Jun 7, 2019, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE A. Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 7, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 10MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Discontinued |
| Jun 23, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 5, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 7, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters